J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
|Articles|February 14, 2019
COA Reviews Highlights From 2018
The Community Oncology Alliance recently released its 2018 Year in Review report, evaluating the successes and highlights from the organization’s many initiatives over the past year.
Advertisement
COA acknowledges that 2018 was a year of strong policy performance, with the organization addressing several important issues that would affect community oncology, such as proposed changes to Medicare and the application of the Medicare sequester cut to Part B reimbursement.
The report also emphasized the organization’s involvement in developing the Oncology Care Model and in finding solutions for the cost of cancer care, as well as the impactful studies produced by COA throughout the year, such as the 2018 Practice Impact Report.
Advertisement
Related to this article
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
The designation expands the investigational immunotherapy’s development across tumor types for patients whose disease progresses after prior treatment, including immune checkpoint inhibition.
Phase 2b data show iopofosine I-131 drives deep, durable responses in relapsed Waldenström macroglobulinemia after BTK inhibitors, with manageable cytopenias.
The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
During a virtual event, Neil M. Iyengar, MD, and participants discussed how approvals for trastuzumab deruxtecan before and after surgery complicate sequencing for patients with HER2-positive early breast cancer.
The oral KRAS G12D inhibitor VS-7375 elicited clinical responses across patients with KRAS G12D–mutant pancreatic, lung, and colorectal cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
2
Durability of PFS and OS Benefit vs. Historical Control
3
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
4
Invikafusp Alfa Receives Second FDA Fast Track Designation for TMB-High Solid Tumors
5